基于多参数MRI的影像组学特征用于乳腺癌新辅助化疗前疗效预测
本研究纳入152例乳腺癌患者,基于T2W、DWI、DCE及其组合构建影像组学特征,并结合临床因素建立列线图模型,用于预测新辅助化疗敏感性及病理完全缓解。联合影像组学特征与列线图模型在训练集和验证集中均显示出较好的区分能力,而临床因素模型性能较低。
要点
- 基于多参数MRI的联合影像组学特征及列线图模型对NAC疗效和pCR具有潜在预测能力。
- 联合模型在训练集和验证集中AUC分别为0.91、0.92和0.93、0.91。
- 临床因素模型预测NAC敏感性和pCR的AUC分别为0.74和0.64,性能较低。
关键影像表现/征象
- 基于T2W成像、扩散加权成像、动态对比增强成像及其组合构建了四种影像组学特征,并计算影像组学评分。
- 分别筛选出20个特征和18个特征用于构建评估NAC敏感性和pCR可能性的影像组学特征。
诊断标准与关键数值
- 联合影像组学特征和列线图模型在训练集预测NAC敏感性和pCR的AUC分别为0.91(95%CI 0.85-0.96)和0.92(95%CI 0.86-0.98)。
- 联合影像组学特征和列线图模型在验证集预测NAC敏感性和pCR的AUC分别为0.93(95%CI 0.86-1.00)和0.91(95%CI 0.82-1.00)。
- 临床因素模型预测NAC敏感性和pCR的AUC分别为0.74(95%CI 0.64-0.84)和0.64(95%CI 0.46-0.82)。
临床应用与阅片要点
- 作者认为联合影像组学特征和列线图模型对预测有效的新辅助化疗具有潜在预测能力,可辅助预后判断和治疗方案指导。
- 作者指出术前评估NAC疗效可指导后续治疗并避免化疗引起的毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the ability of radiomic signatures based on MRI to evaluate the response and efficiency of neoadjuvant chemotherapy (NAC) for treating breast cancers.
METHODS: 152 patients were included in this study at our institution between March 2017 and September 2019. All patients with breast cancer underwent a preoperative breast MRI and the Miller-Payne grading system was applied to evaluate response to NAC. Quantitative parameters were compared between patients with sensitive and insensitive responses to NAC and between those with pathological complete responses (pCR) and non-pCR. Four radiomic signatures were built based on T2W imaging, diffusion-weighted imaging, dynamic contrast-enhanced imaging and their combination, and radiomics scores (Rad-score) were calculated. The combination of the clinical factors and Rad-scores created a nomogram model. Multivariate logistic regression was performed to assess the association between MRI features and independent clinical risk factors.
RESULTS: 20 features and 18 features were selected to build the radiomic signature for evaluating sensitivity and the possibility of pCR, respectively. The combined radiomic signature and nomogram model showed a similar discrimination in the training (AUC 0.91, 0.92, 95% confidence interval [CI], 0.85-0.96, 0.86-0.98) and validation (AUC 0.93, 0.91, 95% CI, 0.86-1.00, 0.82-1.00) sets. The clinical factor model exhibited reduced performance (AUC 0.74, 0.64, 95% CI, 0.64-0.84, 0.46-0.82) in terms of NAC sensitivity and pCR.
CONCLUSIONS: The combined radiomic signature and nomogram model exhibited potential predictive power for predicting effective NAC treatment which can aid in the prognosis and guidance of treatment regimens.
ADVANCES IN KNOWLEDGE: Identifying a means of assessing the efficacy of NAC before surgery can guide follow-up treatment and avoid chemotherapy-induced toxicity.
引用
- Bian T, Wu Z, Lin Q, et al. Radiomic signatures derived from multiparametric MRI for the pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer. Br J Radiol. 2020. PMID: 32822542. doi:10.1259/bjr.20200287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。